Coeptis raises $4.3M in Series A Preferred financing; CEO granted 2.4M options

Z Squared Inc.

Raised $4.3M via sale of 4,300 shares of Series A Preferred at $1,000/share to accredited investors.
Financing led by CJC Investment Trust (entity of board member Christopher Calise).
Series A convertible at $0.40/share; automatic conversion upon $20M+ fundraising.
CEO David Mehalick granted options for 2.4M shares (fully vested, 10-year term) on June 13.
Investors also received 6.45% non-voting equity in new subsidiaries SNAP Biosciences and GEAR Therapeutics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.